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Summary: Haptoglobin (Hp) is a haemoglobin-binding acute phase protein with three genetic types: Hp 1-1, Hp 2-1,
Hp 2-2. We investigated 45 patients during the first 48 hours of acute myocardial infarction, and studied determinant
factors and clinical correlates. Upon hospital admission, serum haptoglobin concentration was increased
(1.95 ± 0.94 g/1, mean ± SD, P < 0.001) versus the reference population (0.97 ± 0.46 g/l, n = 107), independent of
haptoglobin type: 1.84 ± 0.64 g/1 (Hp 1-1, n = 11) (P < 0.01), 1.98 ± 0.79 g/l (Hp 2-1, n = 25) (P < 0.001),
1.98 ± 1.58 g/l (Hp 2-2, n = 9) (P < 0.001). Moreover, during the first hours of hospitalization, a temporal lowering
of haptoglobin was observed suggesting acute haemolysis, independent of the haptoglobin type. Minimal serum hapto-
globin was reached 9.6 ± 5.8 hours after admission. The amplitude of the haptoglobin decrease correlated with initial
serum haptoglobin (r = 0.78) and was more pronounced (P < 0.05) in men (0.53 ± 0.57 g/1) than in women
(0.18 ± 0.17 g/1). Decrease of serum haptoglobin did not correlate with infarct size (based on creatine kinase-MB re-
lease). Out of the other acute phase proteins measured upon admission, only C-reactive protein was significantly
increased (P < 0.05). During the next 36 hours, haptoglobin increased as a result of the acute phase response to myocar-
dial injury. Our findings suggest that acute myocardial infarction is also preceded by an acute phase response, charac-
terized by an initial high haptoglobin and followed by a temporal haptoglobin decrease due to haemolysis.
Introduction
Atherogenesis and acute myocardial infarction are
known to be associated with inflammation (1) and lim-
ited haemolysis. As haptoglobin (Hp) is involved both
in acute phase reaction (2) and haemolysis (3) we
studied the evolution of haptoglobin concentration dur-
ing the early phase of acute myocardial infarction.
Three genetically determined haptoglobin phenotypes
are known: Hp 1-1, Hp 2-1, and Hp 2-2, each with its
type-specific reference values (2, 4). In the days
following acute myocardial infarction, increased hapto-
globin concentrations are found, with a maximum about
one week after onset of acute myocardial infarction
(5—8). In addition to its role as an acute phase reactant,
haptoglobin possibly fulfils regulatory functions during
acute myocardial infarction (7) such as inhibition of
platelet aggregation by crude and highly purified ar
acid-glycoprotein (9). Functional differences between
haptoglobin types are known (2). Inhibition of prosta-
glandin synthesis is type-dependent (2). Haptoglobin
polymorphism has been shown to correlate with severity
and outcome of acute myocardial infarction (7). The aim
of this study was to evaluate haptoglobin concentration
during the first 36 hours after onset of acute myocardial
infarction, and to study determinant factors and clinical
correlates of the observed pattern (haptoglobin type, in-
farct size, acute phase proteins, ...). Inflammation upon
admission was evaluated by measuring the following
acute phase proteins; aracid glycoprotein, arantipro-
teinase (cii-antitrypsin), a2-macroglobulin and C-re-
active protein. As haptoglobin is characterized by a vari-
ation of the carbohydrate moiety as well (2), this hetero-
geneity was also studied.
Materials and Methods
Study protocol
The study inclusion criterion was the presence of significant
Pardee waves (ST elevations of at least 2 mm in at least 2 adjacent
leads) in the electrocardiogram for at least 30 minutes on admis-
sion. Diagnosis of acute myocardial infarction was established ac-
cording to WHO criteria (10). Serum samples from 45 patients
admitted because of acute myocardial infarction (33 men, age: 58.7
± 12.3 years; 12 women, age: 61.6 ± 12.2 years; mean ± SD)
were analyzed. Healthy blood donors (n = 107, age: 41 ±11
years) served as a reference population. Blood was sampled upon
hospital admission, then every 4 hours until the 16th hour, and
further at the 24th, 30th and 36th hour after admission.
Biochemical determinations
Total creatine kinase1) activity was measured at 37 °C according
to IFCC (11) with a RA-1000 analyzer (Technicon, Tarrytown, NY,
USA), using CK-NAC reagents (J. T. Baker, Deventer, The Nether-
lands). Creatine kinase-MB isoenzyme activity was measured using
immunoprecipitation (Isoimmune-CK™, Roche, Nutley, NJ, USA)
(12). Infarct size was calculated out of cumulative creatine kinase-
MB isoenzyme release (13, 14). Serum haptoglobin, αϊ-acid glyco-
protein, ctrantiproteinase, a2-macroglobulin, and C-reactive pro-
') Enzymes:
Creatine kinase (EC 2.7.3.2)
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tein concentrations were determined with a BN Nephelometer
(Behringwerke, Marburg, Germany) (15). Results were expressed
according to IFCC standards (16). Haptoglobin typing was carried
out according to Smithies (17). Variation in the carbohydrate moi-
ety of haptoglobin were studied by affinity chromatography toward
concanavalin A-Sepharose (18).
Statistics
Results are expressed as mean ± standard deviation. Haptoglobin
type frequencies in the patients and reference group were compared
using χ2 testing with Yates' correction. Comparisons between the
amplitude of haptoglobin decrease and infarct size and between the
amplitude of haptoglobin decrease and initial haptoglobin concen-
tration were made using a Spearman rank correlation test. Results
were compared according to haptoglobin type using non-paramet-
ric statistics (Kruskal-Wallis). Statistical significance was consid-
ered at the level of Ρ < 0.05.
Results
Acute phase protein concentration in acute
myocardial infarction upon admission
Upon admission (173 ± 68 min after onset of symptoms,
creatine kinase 209 ± 245 U/l), serum haptoglobin con-
centration in acute myocardial infarction (1.95 ± 0.94
g/1) was increased compared to the reference population
(0.97 ± 0.46 g/l; P < 0.001). Table 1 shows haptoglobin
concentrations according to haptoglobin type. For the
three haptoglobin types, haptoglobin concentration was
significantly higher (P < 0.01 for Hp 1-1, P < 0.001 for
Hp 2-1 and Hp 2-2) in acute myocardial infarction com-
pared to the reference population. Type frequencies were
0.24 (Hp 1-1), 0.56 (Hp 2-1) and, 0.20 (Hp 2-2) for acute
myocardial infarction patients and 0.20 (Hp 1-1), 0.48
(Hp 2-1) and 0.32 (Hp 2-2) for the reference population
(tab. 1). Both distributions were in agreement with the
Hardy-Weinberg equilibrium. Haptoglobin type distribu-
tions of the reference population and of patients were
comparable. Whereas haptoglobin concentration differs
between haptoglobin types in the reference population
(p < 0.001), this difference was not observed in acute
myocardial infarction upon admission (tab. 1).
Table 2 shows the concentrations of C-reactive protein,
α!-acid glycoprotein, di-antiproteinase, a2-macroglobu-
Tab. 1 Serum haptoglobin concentration in acute myocardial in-
farction patients upon admission and in reference population ac-
cording to haptoglobin phenotype
Tab. 2 Concentration of acute phase proteins in acute myocardial
infarction patients upon admission versus reference population
Haptoglobin
phenotype
Hp 1-1
Hp 2-1
Hp 2-2
Reference population
η
21
51
35
Haptoglobin
concentration
(g/1)
1.24 ± 0.51
0.99 ± 0.41
0.75 ± 0.42
Acute myocardial
infarction patients
η
11
25
9
Haptoglobin
concentration
(g/i)a
1.84 ± 0.64*
1.98 ± 0.79**
1.98 ± 1.58**
Acute phase protein
C-reactive protein, mg/1
oti-Antiproteinase, g/1
α ι -Acid glycoprotein, g/1
a2-Macroglobulin, g/1
Haptoglobin, g/1
Relative concanavalin Aa
binding of haptoglobin
Patients
(mean ± SD)
6.4 ±4.9*
1.52 ± 0.35
1.08 ± 0.51
2.02 ± 0.40
1.95 ± 0.94**
0.66 ± 0.19*
Reference
range"
<5
1.46 ± 0.27
0.90 ± 0.20
1.80 ± 0.35
0.97 ± 0.46
0.86 ± 0.07
a
 For acute myocardial infarction patients, serum haptoglobin con-
centration given upon hospital admission.
* P < 0.01; **P< 0.001 compared to the reference population
* P < 0.05, ** P < 0.01
a
 Derived from individual data from a reference population mea-
sured in our laboratory which took part in a multicentre evaluation
program (I.e. (15)).
lin and haptoglobin on admission and compares them
with our reference population (15). Only haptoglobin
and C-reactive protein were increased compared to the
reference population.
Evolution of haptoglobin concentration
during acute myocardial infarction
In acute myocardial infarction, haptoglobin concentra-
tions were serially followed during the first 36 hours
after admission (fig. 1). Upon admission, haptoglobin
concentration was increased. In the following hours, a
temporary lowering of haptoglobin concentration is ob-
served. This initial lowering is followed shortly by a
gradual increase of haptoglobin concentration, which is
compatible with the role of haptoglobin as an acute
phase reactant after acute myocardial infarction. Mini-
mal haptoglobin concentrations were found 9.6 ± 5.8 h
(range: 2.0—33.0 h) after admission. The observed
change from admission in haptoglobin concentration
was 0.44 ± 0.52 g/1 (range 0.03-2.69 g/1) and was com-
parable among haptoglobin types (tab. 3) and not related
to infarct size estimated by creatine kinase-MB isoen-
zyme release (Spearman r = 0.17). Significant differ-
ences in haptoglobin concentration decrease were ob-
served according to gender. For male patients (n = 33),
the haptoglobin decrease was 0.53 ± 0.57 g/1 vs. 0.18
±0.17 g/1 for female patients (n = 12) (P < 0.05). The
decrease of haptoglobin concentration correlated with
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Fig. 1 Evolution of haptoglobin concentration in acute myocar-
dial infarction: at admission (1); at minimal haptoglobin concentra-
tion (2); at 24 hours after minimal haptoglobin concentration (3)
(** P < 0.01, Kruskal-Wallis).
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Tab. 3 Serum haptoglobin decrease and estimated infarct size in
acute myocardial infarction patients according to haptoglobin phe-
notype
Haptoglobin
phenotype
Hp 1-1
Hp 2-1
Hp 2-2
Serum haptoglobin
decrease3 (g/1)
0.30 ±0.19
0.52 ± 0.24
0.56 ± 0.65
Estimated infarct size
(g creatine kinase-
MB equivalent)0
26.6 ± 17.5
17.5 ± 17.0
16.2 ± 13.1
a
 Decrease in serum haptoglobin concentration from admission to
minimal concentration
b
 Creatine kinase-MB isoenzyme equivalent (g) (1. c. (14))
haptoglobin concentration upon admission: y (haptoglo-
bin decrease, g/1) = 0.43 (serum haptoglobin upon ad-
mission, g/1) -0.40; r = 0.78, Sxy = 0.33.
Microheterogeneity of haptoglobin upon
admission
Concanavalin A affinity chromatography showed that 65
± 19% of serum haptoglobin in acute myocardial infarc-
tion upon admission bound to the lectin (tab. 2). The
concanavalin A binding fraction is lower than in the ref-
erence population (86 ± 7%, P < 0.05). No differences
in concanavalin A binding according to haptoglobin
type were observed.
Discussion
In the reference population and in acute myocardial in-
farction patients, the distribution of haptoglobin types
corresponds to other European studies (2). Haptoglobin
type distribution in both controls and acute myocardial
infarction patients was in agreement with the Hardy-
Weinberg equilibrium.
Upon admission, increased haptoglobin concentrations
were found in a large majority of acute myocardial in-
farction patients independently of haptoglobin type.
However, haptoglobin concentration in the reference
population was significantly lower in Hp 2-2 carriers,
which is in accordance to previously published data (2,
4). The observation of a simultaneous increase of hapto-
globin and C-reactive protein is in contrast to normal
concentrations for aracid glycoprotein, arantiprotein-
ase and a2-macroglobulin in acute myocardial infarction
upon admission and points to a stimulation of haptoglo-
bin and C-reactive protein synthesis prior to the infarc-
tion. Haptoglobin and C-reactive protein are acute phase
proteins, whose synthesis is stimulated by interleukin-6
(2). The response of haptoglobin and C-reactive protein
synthesis to interleukin-6 stimulation occurs slowly and
becomes obvious after 24 h. Our data suggest that acute
myocardial infarction is preceded by an acute phase re-
action during the day(s) before the coronary thrombosis.
This agrees with other studies in which the relationship
between infection and inflammatory processes and the
risk for acute myocardial infarction was established (1).
The increased serum haptoglobin concentration in acute
myocardial infarction upon admission is in agreement
with literature (5 — 8). When comparing haptoglobin val-
ues in previous reports (6, 7), after conversion to IFCC
standards, higher haptoglobin concentrations are found
in this study in Hp 2-2 sera, and lower haptoglobin con-
centrations in Hp 1-1 sera. Relative molecular mass dif-
fers between haptoglobin types (Hp 1-1: MT = 80000,
Hp 2-1: MT = 120000, Hp 2-2: MT = 160000). This
leads to different diffusion rates between the haptoglo-
bin types which results in an underestimation of Hp 2-2
concentration with the radial immunodiffusion tech-
nique (2, 4, 19). This might explain the lower Hp 1-1
and higher Hp 2-2 concentrations determined by nephe-
lometry in this study compared to studies using radial
immunodiftusion (6, 7).
After admission, a temporary lowering of haptoglobin
concentration is found in acute myocardial infarction,
which was not reported in previous studies (5—8). The
latter is not surprising, as the minimal haptoglobin con-
centration is observed 9.6 ± 5.8 h after admission and
blood samples for haptoglobin determination in the for-
mer studies were only collected once daily. In our study
the amplitude of the lowering depends on the initial hap-
toglobin concentration. However, this finding should be
viewed with caution. Given a haemolytic pulse as part
of the evolution of acute myocardial infarction, the
decrease in haptoglobin theoretically might be unrelated
to the initial concentration. The initial lowering of hap-
toglobin concentration following acute myocardial in-
farction can be explained by haemoglobin-binding. After
consumption of haptoglobin, haemopexin levels start to
decrease, whereas haptoglobin concentration remains
low (< 0.3 g/1) (3). In this study, complete consumption
of haptoglobin was observed in 2 acute myocardial in-
farction cases (5%). Elimination of haemoglobin-hapto-
globin complexes by the liver occurs faster because of
the rapid recognition by receptors localized at the mem-
brane of liver parenchyma (2). The lowering of hapto-
globin during the first hours after admission suggests a
moderate acute haemolysis. Based on a haemoglobin-
haptoglobin binding ratio of 1 : 1, the observed decrease
in haptoglobin concentration corresponds with a hae-
molysis of ± 10 ml erythrocytes, equivalent to a com-
plete haemolysis of ± 22 ml of blood. This might be
caused by acute changes in red cell survival induced by
regional changes of the blood flow (20). Interestingly,
our observation of haptoglobin lowering differs signifi-
cantly according to gender. Rheological properties of
whole blood are sex-related: total shear stress of whole
blood being lower in females (21). From the second day
of hospitalization, the slowly increasing haptoglobin
concentration takes part of the acute phase reaction.
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The observed haemolysis has consequences for the esti-
mation of acute myocardial infarction size based on the
release of -hydroxybutyrate dehydrogenase (EC
1.1.1.30) (22) since erythrocytes contain considerable
amounts of this enzyme. So, the observed haemolysis
may cause an overestimation of acute myocardial infarc-
tion size when using methods based on release of a-
hydroxybutyrate dehydrogenase.
The difference in affinity of haptoglobin towards con-
canavalin A in acute myocardial infarction on admis-
sion suggests an altered glycosylation of haptoglobin
prior to acute myocardial infarction. Concanavalin A
has an affinity towards mannose and glucose related
structures (18). Increase in sialic acid content reduces
the binding towards concanavalin A (23). The conca-
navalin A non-binding fraction of haptoglobin does
not form complexes with haemoglobin (24), so the
haemoglobin-binding capacity of haptoglobin is re-
duced during the early phase of acute myocardial in-
farction. Furthermore, recent findings postulate a role
for haptoglobin in homing and trafficking of B lym-
phocytes (25).
The increased haptoglobin concentration in acute myo-
cardial infarction upon admission, followed by a tempo-
rary decrease due to a limited haemolysis and the altered
glycosylation of haptoglobin in acute myocardial infarc-
tion upon admission suggest an involvement of hapto-
globin in the complex mechanism leading to acute myo-
cardial infarction. Further studies will be needed to in-
vestigate the specificity of our findings and the interac-
tion between haptoglobin and the complex mechanism
leading to acute myocardial infarction.
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